Scholarlink

Background <p>Hepatitis C virus (HCV) infection can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The advent of direct-acting antivirals (DAA) has transformed HCV treatment, achieving high cure rates. This study aimed to evaluate fibrotic, metabolic and clinical improvements in chronic HCV patients treated with DAA in low resource settings.</p> Methods <p>An institution-based prospective cohort study was conducted from February 1 to July 30, 2023 to collect data face-to-face using a structured questionnaire and data abstraction sheet. Statistical analysis was performed using Statistical Package for the Social Sciences version 26. Continuous variables were expressed as mean ± standard deviation, while categorical variables were presented as frequencies and percentages. Paired t-tests were used to compare baseline, third and sixth months post sustained virologic response (SVR) data, with statistical significance set at <i>P</i> &lt; 0.05.</p> Results <p>A total of 102 patients were enrolled (mean age 47.67 ± 12.7 years); and most were female (65.7%). Significant reductions were observed in liver enzymes: Aspartate aminotransferase and Alanine aminotransferase decreased at three and six month post-SVR (<i>P</i> &lt; 0.001). Hepatic synthetic function improved, with serum albumin rising and international normalized ratio declining at both follow-ups (<i>P</i> &lt; 0.001). Total bilirubin decreased significantly at three (<i>P</i> = 0.007) and six months (<i>P</i> = 0.001). Model for End Stage Liver Disease scores declined at three and six months (<i>P</i> &lt; 0.001). Aspartate aminotransferase to Platelet ratio index scores and Fibrosis-4index score, demonstrated significant reductions at both follow up (<i>P</i> &lt; 0.001).</p> Conclusions <p>Direct-acting antivirals therapy in chronic HCV patients resulted in a statistically significant improvements in liver function, clinical outcomes, and fibrosis levels by the third and sixth months post SVR.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fibrotic, metabolic and clinical improvements in patients with chronic hepatitis C treated with direct-acting antiviral therapy in a resource limited setting: a prospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Kinfe Woldu Ekubazgi,
  • Miftah Dellil,
  • Beshada Zerfu Woldegeorgis,
  • Kaleb Assefa Berhane,
  • Sewale Anagaw,
  • Henok Fisseha

摘要

Background

Hepatitis C virus (HCV) infection can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The advent of direct-acting antivirals (DAA) has transformed HCV treatment, achieving high cure rates. This study aimed to evaluate fibrotic, metabolic and clinical improvements in chronic HCV patients treated with DAA in low resource settings.

Methods

An institution-based prospective cohort study was conducted from February 1 to July 30, 2023 to collect data face-to-face using a structured questionnaire and data abstraction sheet. Statistical analysis was performed using Statistical Package for the Social Sciences version 26. Continuous variables were expressed as mean ± standard deviation, while categorical variables were presented as frequencies and percentages. Paired t-tests were used to compare baseline, third and sixth months post sustained virologic response (SVR) data, with statistical significance set at P < 0.05.

Results

A total of 102 patients were enrolled (mean age 47.67 ± 12.7 years); and most were female (65.7%). Significant reductions were observed in liver enzymes: Aspartate aminotransferase and Alanine aminotransferase decreased at three and six month post-SVR (P < 0.001). Hepatic synthetic function improved, with serum albumin rising and international normalized ratio declining at both follow-ups (P < 0.001). Total bilirubin decreased significantly at three (P = 0.007) and six months (P = 0.001). Model for End Stage Liver Disease scores declined at three and six months (P < 0.001). Aspartate aminotransferase to Platelet ratio index scores and Fibrosis-4index score, demonstrated significant reductions at both follow up (P < 0.001).

Conclusions

Direct-acting antivirals therapy in chronic HCV patients resulted in a statistically significant improvements in liver function, clinical outcomes, and fibrosis levels by the third and sixth months post SVR.